Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

ABSTRACT:

Background

Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was carried out after long-term follow-up.

Patients and methods

EXAM compared cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomized (2:1) to cabozantinib (140 mg/day) or placebo. Final OS and updated safety data are reported.

Results

Minimum follow-up was 42 months. Kaplan-Meier analysis showed a 5.5-month increase in median OS with c

SUBMITTER: Schlumberger M 

PROVIDER: S-EPMC5834040 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature